CytomX’s Probody T-Cell Platform Produces Astellas Pact
Bispecifics collaboration with Astellas May Be Worth $1.6bn For CytomX
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.